PALO ALTO--(BUSINESS WIRE)--Carbylan BioSurgery, Inc., a medical device company focused on development of bioresponsive medical products for osteoarthritis and chronic rhinosinusitis, today announced the closing of a $20 million Series B preferred stock financing. The financing was led by Vivo Ventures and included existing investors Alta Partners and InterWest Partners. In connection with the financing, Albert Cha, MD PhD, Managing Partner at Vivo Ventures, will join Carbylan's board of directors.